Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.80) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.04. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

Shares of CGEM stock opened at $7.62 on Wednesday. Cullinan Therapeutics has a 1 year low of $6.85 and a 1 year high of $28.11. The firm has a market capitalization of $449.69 million, a PE ratio of -2.68 and a beta of -0.07. The stock has a fifty day moving average of $8.08 and a two-hundred day moving average of $10.51.

Insider Buying and Selling at Cullinan Therapeutics

In other news, insider Jeffrey Alan Jones sold 4,895 shares of the firm's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $41,754.35. Following the completion of the sale, the insider now directly owns 174,164 shares of the company's stock, valued at $1,485,618.92. This trade represents a 2.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total value of $106,872.37. Following the completion of the transaction, the chief executive officer now owns 430,621 shares in the company, valued at $3,673,197.13. The trade was a 2.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

CGEM has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an "overweight" rating and issued a $35.00 target price (down previously from $38.00) on shares of Cullinan Therapeutics in a research report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, April 16th. Finally, UBS Group dropped their target price on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $32.00.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.